STARKS DANIEL J 4

What Happened
Daniel J. Starks, a director of Abbott Laboratories (ABT), made open-market purchases of a total of 10,000 ABT shares on February 4, 2026. The trades were reported on a Form 4 filed Feb 6, 2026. The transactions consist of 4,967 shares at $109.14 ($542,092) and 5,033 shares at $108.33 ($545,239), for total consideration of $1,087,331 (average ≈ $108.73 per share). These were purchases (acquisitions), which insiders often view as a more informative signal than routine sales, though motives are not disclosed.

Key Details

• Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (appears timely — within the 2-business-day window).
• Trades: 4,967 shares @ $109.14 = $542,092 (reported with weighted-average note F1); 5,033 shares @ $108.33 = $545,239 (weighted-average note F2).
• Combined: 10,000 shares for $1,087,331; avg price ≈ $108.73/share.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnotes: F1 and F2 state the reported prices are weighted averages and that the shares were executed in multiple transactions with price ranges (F1 range ≈ $108.8150–$109.5204; F2 range ≈ $107.7700–$108.7150) and that full breakdowns are available on request. F3 notes the shares are held in the Alynne Starks 2012 Irrevocable Trust, for which the reporting person is sole trustee.

Context

• Code P indicates an open-market or private purchase (here, open-market buys). Purchases by directors can signal confidence but do not prove future performance; avoid assuming motive.
• No derivative exercises, gifts, or tax-withholding events are reported in this filing excerpt.